LUND, Sweden ―Today on World Pancreatic Cancer Day, pancreatic cancer remains to show one of the lowest survival rates among all major cancers. In nearly every country, pancreatic cancer is the only cancer with a single-digit five-year survival rate (2-9 percent). Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer, and an estimated 985 will die from the disease. It is estimated that by 2020, 418,000 new cases will be diagnosed globally.
Online event in Sweden on World Pancreatic Cancer Day
World Pancreatic Cancer Day Sweden in 2017 will be an online event that will be focused on the importance of early detection in pancreatic cancer. Please join online on November 16th, starting 09.00 Swedish time here: https://www.worldpancreaticcancerday.se/
Despite efforts to find new therapeutics, early surgery remains the best hope of increased survival. Therefore, the main message from the organizers of this year’s World Pancreatic Cancer Day is: If pancreatic cancer is found early, it is more treatable so visiting your doctor could save your life!
Working in a consortium with leading experts and patient groups, the Swedish company Immunovia is leading efforts to develop the first rapid and accurate blood test for early diagnosis.
“These latest statistics reinforce the fact that without an accurate early stage test for pancreatic cancer, thousands of patients around the world with this deadly disease will not receive treatment early enough for there to be any chance of even short term survival.”, says Mats Grahn, CEO of Immunovia. “I am pleased to report that our clinical study program, designed to provide solid proof of the reliability of Immunovia´s novel blood biomarker array for early diagnosis of pancreatic cancer is well underway, as planned. This is an urgent mission and we are collaborating with leading institutions in Europe and the United States to bring the test to the healthcare sector as quickly as possible.”
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Email: [email protected]
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com ).
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com .
About World Pancreatic Cancer Day
The World Pancreatic Cancer Day is organized by the World Pancreatic Cancer Coalition, http://www.worldpancreaticcancercoalition.org/
Statement from the World Pancreatic Cancer Day website
On November 16, 2017, people around the world will unite to Demand Better in the fight against the world’s toughest cancer. The World Pancreatic Cancer Coalition has brought together more than 60 organizations from 27 countries and six continents to raise awareness and inspire action on World Pancreatic Cancer Day. Through this combined effort, we are bringing greater attention, awareness, and better outcomes to this deadly disease.
Currently, there is no screening test or early detection method for pancreatic cancer. Some are in development – another sign of the progress happening in the field that needs greater attention and funding support.
Early diagnosis is vital, so listen to your body and don’t ignore the signs. If you have symptoms, speak to your healthcare provider as soon as you can.
Powered by WPeMatico